Risk of malignancy in thyroid nodules Bethesda III sub classification into nuclear atypia and architectural atypia. A retrospective study

References

1. 1.↵
   1. Flemban AF,
   2. Kabrah S,
   3. Alahmadi H,
   4. Alqurashi RK,
   5. Turaes AS,
   6. Almaghrabi R et al.

   Patterns of Thyroid Cancer Mortality and Incidence in Saudi Arabia: A 30-Year Study. Diagnostics 2022; 12.
2. 2.↵
   1. Alqahtani WS,
   2. Almufareh NA,
   3. Domiaty DM,
   4. Albasher G,
   5. Alduwish MA,
   6. Alkhalaf H et al.

   Epidemiology of cancer in Saudi Arabia thru 2010–2019: a systematic review with constrained meta-analysis. AIMS Public Health 2020; 7.
3. 3.↵
   1. Cibas ES,
   2. Ali SZ.

   The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2017; 27.
4. 4.↵
   1. Ali SZ,
   2. Baloch ZW,
   3. Cochand-Priollet B,
   4. Schmitt FC,
   5. Vielh P,
   6. Vanderlaan PA.

   The 2023 Bethesda System for Reporting Thyroid Cytopathology. Thyroid 2023; 33.
5. 5.↵
   1. Erdogan-Durmus S,
   2. Balta H,
   3. Demirtas R,
   4. Kurt A.

   Malignancy rates of atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) cases: A tertiary center study. Acta Endocrinol (Copenh) 2021; 17.
6. 6.↵
   1. Ioachim D.

   The Bethesda System for Reporting Thyroid Cytopathology 2nd Edition Revised 2018. Acta Endocrinologica (Bucharest) 2018; 14.
7. 7.↵
   1. Johnson DN,
   2. Cavallo AB,
   3. Uraizee I,
   4. Tanager K,
   5. Lastra RR,
   6. Antic T et al.

   A proposal for separation of nuclear atypia and architectural atypia in Bethesda Category III (AUS/FLUS) based on differing rates of thyroid malignancy. Am J Clin Pathol 2019; 151.
8. 8.
   1. Glass RE,
   2. Levy JJ,
   3. Motanagh SA,
   4. Vaickus LJ,
   5. Liu X.

   Atypia of undetermined significance in thyroid cytology: Nuclear atypia and architectural atypia are associated with different molecular alterations and risks of malignancy. Cancer Cytopathol 2021; 129.
9. 9.↵
   1. Rosario PW,
   2. Calsolari MR.

   Importance of cytological subclassification of thyroid nodules with Bethesda category III cytology (AUS/FLUS) into architectural atypia only and nuclear atypia: A prospective study. Diagn Cytopathol 2017; 45.
10. 10.↵
    1. Mosca L,
    2. Ferraz da Silva LF,
    3. Carneiro PC,
    4. Chacon DA,
    5. Furtado de Araujo-Neto VJ,
    6. Furtado de Araujo-Filho VJ et al.

    Malignancy rates for bethesda III subcategories in thyroid fine needle aspiration biopsy (FNAB). Clinics 2018; 73.
11. 11.↵
    1. Liu X,
    2. Wang J,
    3. Du W,
    4. Dai L,
    5. Fang Q.

    Predictors of malignancy in thyroid nodules classified as Bethesda Category III. Front Endocrinol (Lausanne) 2022; 13.
12. 12.↵
    1. Zarif H,
    2. Ghandurah S,
    3. Al-Garni M,
    4. Binmahfooz S,
    5. Alsaywid B,
    6. Satti M.

    Thyroid nodules cytopathology applying the Bethesda system with histopathological correlation. Saudi J Med Med Sci 2018; 6.
13. 13.↵
    1. Zhao H,
    2. Guo HQ,
    3. Zhao LL,
    4. Cao J,
    5. Sun Y,
    6. Wang C et al.

    Subclassification of the Bethesda Category III (AUS/FLUS): A study of thyroid FNA cytology based on ThinPrep slides from the National Cancer Center in China. Cancer Cytopathol 2021; 129.
14. 14.↵
    1. Kim SJ,
    2. Roh J,
    3. Baek JH,
    4. Hong SJ,
    5. Shong YK,
    6. Kim WB et al.

    Risk of malignancy according to sub-classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology. Cytopathology 2017; 28.
15. 15.↵
    1. Huang J,
    2. Shi H,
    3. Song M,
    4. Liang J,
    5. Zhang Z,
    6. Chen X et al.

    Surgical outcome and malignant risk factors in patients with thyroid nodule classified as Bethesda Category III. Front Endocrinol (Lausanne) 2021; 12.